urothelial cancer

Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
Pharmaceutical Business Review
Seagen
Astellas
clinical trials
EV-201
urothelial cancer
Flag link:
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
Flag link:
Esmo 2020 – some backing for Beigene’s unusual combo approach
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
ESMO
BeiGene
urothelial cancer
Flag link:
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
Flag link:
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
Xconomy
Urogen
urothelial cancer
FDA
Jelmyto
Flag link:
Seattle Genetics Issue Update on Padcev Label Expansion Study
Seattle Genetics Issue Update on Padcev Label Expansion Study
Yahoo/Zacks.com
Seattle Genetics
Padcev
Merck
Keytruda
urothelial cancer
Flag link:
Roche's Tecentriq fails trial in form of urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Flag link:
Here's Why Seattle Genetics Climbed 17.6% in September
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
Flag link:
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
Flag link:
Seattle Genetics drug could provide new option for bladder cancer patients
Seattle Genetics drug could provide new option for bladder cancer patients
Biopharma Dive
Seattle Genetics
ASCO 2019
enfortumab vedotin
urothelial cancer
Flag link:
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
CP WIre
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Flag link:
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Flag link:
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
BioCentury
Urogen
UGN-101
MitoGel
urothelial cancer
Liz Barrett
Flag link:
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Upcoming events – Phase III readouts loom for Urogen and Mediwound
EP Vantage
Urogen
clinical trials
UGN-101
urothelial cancer
MediWound
NexoBrid
devices
burns
Flag link:
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Yahoo/Zacks.com
JNJ
erdafitinib
urothelial cancer
Flag link:
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
Flag link:
2013 GU: Dendreon's Neuvenge, A First Look At The Clinical Trial Results
2013 GU: Dendreon's Neuvenge, A First Look At The Clinical Trial Results
Seeking Alpha
Dendreon
Neuvenge
urothelial cancer
Flag link: